<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Truth About Skin Care &#187; September 11</title>
	<atom:link href="http://thetruthaboutskincare.com/tag/september-11/feed/" rel="self" type="application/rss+xml" />
	<link>http://thetruthaboutskincare.com</link>
	<description>We review the best wrinkle creams &#38; the best anti aging creams (plus the worst skin care products).</description>
	<lastBuildDate>Tue, 07 Sep 2010 23:57:17 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Theravance And Astellas Announce The Commercial Launch Of VIBATIVTM (telavancin) In The United States</title>
		<link>http://thetruthaboutskincare.com/theravance-and-astellas-announce-the-commercial-launch-of-vibativtm-telavancin-in-the-united-states/</link>
		<comments>http://thetruthaboutskincare.com/theravance-and-astellas-announce-the-commercial-launch-of-vibativtm-telavancin-in-the-united-states/#comments</comments>
		<pubDate>Sat, 07 Nov 2009 03:20:03 +0000</pubDate>
		<dc:creator>SkinDoc</dc:creator>
				<category><![CDATA[Skin Care News]]></category>
		<category><![CDATA[Adult Patients]]></category>
		<category><![CDATA[Astellas Pharma Us]]></category>
		<category><![CDATA[Astellas Pharma Us Inc]]></category>
		<category><![CDATA[Fda]]></category>
		<category><![CDATA[Food And Drug]]></category>
		<category><![CDATA[Food And Drug Administration]]></category>
		<category><![CDATA[Food And Drug Administration Fda]]></category>
		<category><![CDATA[Gram Positive Bacteria]]></category>
		<category><![CDATA[Launch]]></category>
		<category><![CDATA[Mrsa]]></category>
		<category><![CDATA[Nasdaq]]></category>
		<category><![CDATA[September 11]]></category>
		<category><![CDATA[Skin And Skin]]></category>
		<category><![CDATA[Skin Structure Infections]]></category>
		<category><![CDATA[Staphylococcus Aureus]]></category>
		<category><![CDATA[Strains]]></category>
		<category><![CDATA[Telavancin]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[Thrx]]></category>
		<category><![CDATA[United States]]></category>

		<guid isPermaLink="false">http://thetruthaboutskincare.com/theravance-and-astellas-announce-the-commercial-launch-of-vibativtm-telavancin-in-the-united-states/</guid>
		<description><![CDATA[Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV™ (telavancin) in the United States. On September 11, 2009, the U.S. Food and Drug Administration (FDA) approved VIBATIV for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus [...]]]></description>
			<content:encoded><![CDATA[<p>Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV™ (telavancin) in the United States. On September 11, 2009, the U.S. Food and Drug Administration (FDA) approved VIBATIV for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.</p>
]]></content:encoded>
			<wfw:commentRss>http://thetruthaboutskincare.com/theravance-and-astellas-announce-the-commercial-launch-of-vibativtm-telavancin-in-the-united-states/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
